Repligen (NASDAQ:RGEN) Shares Gap Up to $123.15

Shares of Repligen Co. (NASDAQ:RGEN) gapped up before the market opened on Wednesday . The stock had previously closed at $123.15, but opened at $126.74. Repligen shares last traded at $127.75, with a volume of 184,009 shares.

Analysts Set New Price Targets

RGEN has been the subject of a number of research analyst reports. Deutsche Bank Aktiengesellschaft raised shares of Repligen from a “hold” rating to a “buy” rating and dropped their target price for the company from $180.00 to $155.00 in a report on Wednesday. JPMorgan Chase & Co. reduced their price objective on Repligen from $230.00 to $200.00 and set an “overweight” rating for the company in a report on Thursday, May 2nd. Finally, Guggenheim initiated coverage on Repligen in a report on Tuesday, June 18th. They issued a “neutral” rating on the stock. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $193.00.

Repligen Stock Down 0.3 %

The stock has a market cap of $7.07 billion, a price-to-earnings ratio of 506.38, a P/E/G ratio of 4.24 and a beta of 1.04. The company has a current ratio of 6.35, a quick ratio of 5.24 and a debt-to-equity ratio of 0.26. The firm’s 50 day moving average is $152.33 and its two-hundred day moving average is $174.10.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported $0.28 earnings per share for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.01). The firm had revenue of $151.31 million during the quarter, compared to analyst estimates of $150.06 million. Repligen had a net margin of 2.44% and a return on equity of 3.95%. The business’s quarterly revenue was down 17.1% on a year-over-year basis. During the same period in the prior year, the firm earned $0.64 EPS. On average, sell-side analysts predict that Repligen Co. will post 1.46 EPS for the current year.

Insider Activity at Repligen

In other Repligen news, CEO Anthony Hunt sold 20,072 shares of Repligen stock in a transaction dated Tuesday, May 21st. The stock was sold at an average price of $168.26, for a total value of $3,377,314.72. Following the completion of the sale, the chief executive officer now owns 163,177 shares in the company, valued at approximately $27,456,162.02. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, Director Martin D. Madaus purchased 1,615 shares of the company’s stock in a transaction on Friday, June 14th. The stock was bought at an average cost of $124.94 per share, for a total transaction of $201,778.10. Following the completion of the purchase, the director now directly owns 4,613 shares of the company’s stock, valued at approximately $576,348.22. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Anthony Hunt sold 20,072 shares of Repligen stock in a transaction dated Tuesday, May 21st. The shares were sold at an average price of $168.26, for a total value of $3,377,314.72. Following the completion of the transaction, the chief executive officer now directly owns 163,177 shares in the company, valued at $27,456,162.02. The disclosure for this sale can be found here. Insiders own 1.20% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the business. YHB Investment Advisors Inc. purchased a new position in shares of Repligen in the 1st quarter valued at $26,000. Lazard Asset Management LLC increased its holdings in Repligen by 206.1% in the 1st quarter. Lazard Asset Management LLC now owns 202 shares of the biotechnology company’s stock valued at $36,000 after purchasing an additional 136 shares in the last quarter. Benjamin F. Edwards & Company Inc. raised its position in Repligen by 152.1% in the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 242 shares of the biotechnology company’s stock valued at $43,000 after purchasing an additional 146 shares during the period. Principal Securities Inc. acquired a new position in shares of Repligen during the fourth quarter worth about $48,000. Finally, CWM LLC lifted its stake in shares of Repligen by 19.9% during the first quarter. CWM LLC now owns 361 shares of the biotechnology company’s stock worth $66,000 after purchasing an additional 60 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.